The North America Hemophilia Market should witness market growth of 5.2% CAGR during the forecast period (2023-2030).
The market is also anticipated to benefit from increasing funds for hemophilia research over the projected period. For instance, a multi-institutional project to develop hemophilia medications will be led by a researcher from the Indiana University School of Medicine in March 2022. This project is funded with USD 12 million from the National Heart, Lung, and Blood Institute. This will pave the way for the creation of cutting-edge hemophilia treatments, which is anticipated to propel the market's expansion over the anticipated time frame.
The market is primarily driven by the approval of gene therapy for the treatment of hemophilia and the existence of numerous other candidates in various pipeline stages. In addition, rising government support for programs aimed at early diagnosis in newborns and increased awareness of hemophilia disorders. Additionally, the expansion of the market is anticipated to be boosted by an increase in product approvals by the US Food and Drug Administration.
The therapeutic advances in hemophilia have resulted in a wave of new FDA-approved agents. Additionally, the rising consumer awareness about technologically advanced products, the rising prevalence of hemophilia, and the existence of a sizable patient pool are the main factors propelling the growth of the market in the region. In the United States, there were 18,398 hemophilia patients in 2021, comprising 14,098 hemophilia A and 4,300 cases of hemophilia B, according to the World Federation of Hemophilia 2021 study. According to the estimate, there were around 4050 hemophilia cases in Canada in 2021, including 3,323 hemophilia A and 727 cases of hemophilia B.
Due to the greater use of hemophilia therapeutics, the large number of hemophilia cases in these regions is anticipated to fuel market expansion. A gene for an inherited bleeding problem is carried by around 300,000 Canadians, according to the Canadian Hemophilia Society. At least 30,000 Canadians, or one in ten of these individuals, have symptoms severe enough to warrant medical attention. Many of them have received inadequate diagnoses. In the Canadian network of comprehensive care clinics for hereditary bleeding disorders, only 10,000 persons with inherited bleeding disorders are listed. As a result, throughout the forecast period, the market in this region is anticipated to be driven by rising research and development into the creation of new, effective medicines as well as rising hemophilia prevalence.
The US market dominated the North America Hemophilia Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $5,736.1 million by 2030. The Canada market is experiencing a CAGR of 7.6% during (2023-2030). Additionally, The Mexico market would exhibit a CAGR of 6.6% during (2023-2030).
Based on Distribution Channel, the market is segmented into Specialty Pharmacies, and Hospital Pharmacies. Based on Type, the market is segmented into Hemophilia A, Hemophilia B, and Others. Based on Treatment Type, the market is segmented into Prophylaxis, On-demand, and Cure. Based on Therapy, the market is segmented into Factor Replacement Therapy (Recombinant Factor Concentrates, and Plasma-derived Factor Concentrates), Desmopressin & Fibrin Sealants, and Gene Therapy & Monoclonal Antibodies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, CSL Limited (CSL Behring), Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB (Investor AB) and Sanofi S.A.
The market is also anticipated to benefit from increasing funds for hemophilia research over the projected period. For instance, a multi-institutional project to develop hemophilia medications will be led by a researcher from the Indiana University School of Medicine in March 2022. This project is funded with USD 12 million from the National Heart, Lung, and Blood Institute. This will pave the way for the creation of cutting-edge hemophilia treatments, which is anticipated to propel the market's expansion over the anticipated time frame.
The market is primarily driven by the approval of gene therapy for the treatment of hemophilia and the existence of numerous other candidates in various pipeline stages. In addition, rising government support for programs aimed at early diagnosis in newborns and increased awareness of hemophilia disorders. Additionally, the expansion of the market is anticipated to be boosted by an increase in product approvals by the US Food and Drug Administration.
The therapeutic advances in hemophilia have resulted in a wave of new FDA-approved agents. Additionally, the rising consumer awareness about technologically advanced products, the rising prevalence of hemophilia, and the existence of a sizable patient pool are the main factors propelling the growth of the market in the region. In the United States, there were 18,398 hemophilia patients in 2021, comprising 14,098 hemophilia A and 4,300 cases of hemophilia B, according to the World Federation of Hemophilia 2021 study. According to the estimate, there were around 4050 hemophilia cases in Canada in 2021, including 3,323 hemophilia A and 727 cases of hemophilia B.
Due to the greater use of hemophilia therapeutics, the large number of hemophilia cases in these regions is anticipated to fuel market expansion. A gene for an inherited bleeding problem is carried by around 300,000 Canadians, according to the Canadian Hemophilia Society. At least 30,000 Canadians, or one in ten of these individuals, have symptoms severe enough to warrant medical attention. Many of them have received inadequate diagnoses. In the Canadian network of comprehensive care clinics for hereditary bleeding disorders, only 10,000 persons with inherited bleeding disorders are listed. As a result, throughout the forecast period, the market in this region is anticipated to be driven by rising research and development into the creation of new, effective medicines as well as rising hemophilia prevalence.
The US market dominated the North America Hemophilia Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $5,736.1 million by 2030. The Canada market is experiencing a CAGR of 7.6% during (2023-2030). Additionally, The Mexico market would exhibit a CAGR of 6.6% during (2023-2030).
Based on Distribution Channel, the market is segmented into Specialty Pharmacies, and Hospital Pharmacies. Based on Type, the market is segmented into Hemophilia A, Hemophilia B, and Others. Based on Treatment Type, the market is segmented into Prophylaxis, On-demand, and Cure. Based on Therapy, the market is segmented into Factor Replacement Therapy (Recombinant Factor Concentrates, and Plasma-derived Factor Concentrates), Desmopressin & Fibrin Sealants, and Gene Therapy & Monoclonal Antibodies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, CSL Limited (CSL Behring), Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB (Investor AB) and Sanofi S.A.
Scope of the Study
By Distribution Channel
- Specialty Pharmacies
- Hospital Pharmacies
By Type
- Hemophilia A
- Hemophilia B
- Others
By Treatment Type
- Prophylaxis
- On-demand
- Cure
By Therapy
- Factor Replacement Therapy
- Recombinant Factor Concentrates
- Plasma-derived Factor Concentrates
- Desmopressin & Fibrin Sealants
- Gene Therapy & Monoclonal Antibodies
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Takeda Pharmaceutical Company Limited
- CSL Limited (CSL Behring)
- Pfizer, Inc.
- Bayer AG
- F.Hoffmann-La Roche Ltd.
- Novo Nordisk A/S
- Octapharma AG
- BioMarin Pharmaceutical Inc.
- Swedish Orphan Biovitrum AB (Investor AB)
- Sanofi S.A.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market At a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. North America Hemophilia Market by Distribution Channel
Chapter 6. North America Hemophilia Market by Type
Chapter 7. North America Hemophilia Market by Treatment Type
Chapter 8. North America Hemophilia Market by Therapy
Chapter 9. North America Hemophilia Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Takeda Pharmaceutical Company Limited
- CSL Limited (CSL Behring)
- Pfizer, Inc.
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Novo Nordisk A/S
- Octapharma AG
- BioMarin Pharmaceutical Inc.
- Swedish Orphan Biovitrum AB (Investor AB)
- Sanofi S.A.
Methodology
LOADING...
